Study characteristics |
Patient Sampling |
During the two years, from January 1989 to December 1990, 50 patients with hepatocellular carcinoma plus liver cirrhosis (37 males and 13 females) and 50 patients with liver cirrhosis alone (37 males and 13 females) were included.
Age range not reported. Males 74% |
Patient characteristics and setting |
|
Index tests |
The serum AFP was measured using an a‐Fetoprotein Radioimmunoassay Kit (Dinabot Laboratories, Tokyo, Japan), and its normal level is less than 20 ng/mL. |
Target condition and reference standard(s) |
In 37 out of the 50 hepatocellular carcinoma patients, diagnosis was made by histological examination (biopsy and necropsy); in the remainder, it was based on markedly elevated serum AFP levels (400 ng/mL), space‐occupied lesions demonstrable by various imaging techniques, and typical computed tomographic and/or angiographic findings [7‐10]. In the group of patients with liver cirrhosis, the diagnosis was made on liver biopsy in 40 patients, and on clinical, biochemical, and computed tomographical findings in the remaining 10 patients. |
Flow and timing |
No information on interval between index test and reference standard |
Comparative |
|
Notes |
No information on funding or conflicts of interest |
Methodological quality |
Item |
Authors' judgement |
Risk of bias |
Applicability concerns |
DOMAIN 1: Patient Selection |
Was a consecutive or random sample of patients enrolled? |
No |
|
|
Was a case‐control design avoided? |
No |
|
|
Did the study avoid inappropriate exclusions? |
Unclear |
|
|
Could the selection of patients have introduced bias? |
|
High risk |
|
Are there concerns that the included patients and setting do not match the review question? |
|
|
High |
DOMAIN 2: Index Test (AFP) |
Were the index test results interpreted without knowledge of the results of the reference standard? |
No |
|
|
If a threshold was used, was it pre‐specified? |
Yes |
|
|
Could the conduct or interpretation of the index test have introduced bias? |
|
High risk |
|
Are there concerns that the index test, its conduct, or interpretation differ from the review question? |
|
|
Low concern |
DOMAIN 2: Index Test (US+AFP) |
DOMAIN 2: Index Test (US) |
DOMAIN 3: Reference Standard |
Is the reference standards likely to correctly classify the target condition? |
Yes |
|
|
Were the reference standard results interpreted without knowledge of the results of the index tests? |
No |
|
|
Could the reference standard, its conduct, or its interpretation have introduced bias? |
|
High risk |
|
Are there concerns that the target condition as defined by the reference standard does not match the question? |
|
|
Low concern |
DOMAIN 4: Flow and Timing |
Was there an appropriate interval between index test and reference standard? |
Unclear |
|
|
Did all patients receive the same reference standard? |
No |
|
|
Were all patients included in the analysis? |
Yes |
|
|
Could the patient flow have introduced bias? |
|
High risk |
|